Vivifi Medical's Non-Surgical BPH Bet Lands Over $2 Million in Federal Grants

For millions of men, the treatment path for an enlarged prostate is a choice between daily pills with side effects or invasive surgery with a long recovery. Vivifi Medical, a Houston-based device startup, is betting there is a third way. Its lead program, ReFlow, targets the vascular and hormonal drivers of benign prostatic hyperplasia (BPH) through a minimally invasive, non-transurethral procedure the company says could be performed in minutes under local anesthesia [Vivifi Medical, retrieved 2026]. It is a bet on a new mechanism of action, one that has so far convinced not just venture investors but the National Institutes of Health and the National Science Foundation, which have awarded the company over $2 million in non-dilutive grants [Perplexity Sonar Pro Brief, retrieved 2026]. The company is also developing a separate device for varicocele, a common cause of male infertility.

A vascular wedge into a crowded market

The standard of care for BPH is bifurcated. For mild to moderate symptoms, it is a daily regimen of alpha-blockers or 5-alpha-reductase inhibitors, medications that can cause dizziness, sexual dysfunction, and require lifelong use. For more severe cases, the mainstay is transurethral resection of the prostate (TURP), a surgical procedure that removes obstructive tissue but carries risks of bleeding, infection, and retrograde ejaculation. A crowded field of minimally invasive surgical therapies (MISTs) has emerged to bridge this gap, using heat, water vapor, or implants to ablate or reshape the prostate, but most still work by physically reducing tissue volume [Vivifi Medical, retrieved 2026].

Vivifi's ReFlow takes a different path. The company's hypothesis is that altering the blood supply to the prostate can change its hormonal environment and reduce growth, addressing the condition's root cause rather than its physical symptom of obstruction. The procedure, which the company says would take 10 to 15 minutes, would use an FDA-approved vascular coupler to reroute blood flow [ClinicalTrial.be, retrieved 2026]. This approach leverages existing safety data for anastomotic devices, a regulatory strategy that could potentially streamline its path to the clinic [TrialX, retrieved 2026]. The company has reported completing nine-patient open surgical feasibility studies to demonstrate procedural viability [LinkedIn, Feb 2026].

Funding a long runway with non-dilutive capital

Founded in 2010 by Tushar Sharma, Vivifi has pursued a capital-efficient strategy heavily reliant on government grants. Public records show the company has systematically secured awards from the NSF and NIH's SBIR programs, a critical source of early-stage funding for high-risk biomedical research. This grant funding provides a long, non-dilutive runway to advance preclinical work.

NSF SBIR Phase I | 0.256 | M USD
NSF SBIR Phase II | 1.000 | M USD
NIH/NIDDK SBIR | 0.325 | M USD
NSF SBIR Phase IIB | 0.500 | M USD

This foundation of grant capital was supplemented by a seed investment from Robinson Ventures in May 2024, though the amount was undisclosed [Robinson Ventures, May 2024]. Tracxn data suggests a separate seed round of $2.99 million closed in September 2024, though the lead investor is not named [Tracxn, retrieved 2026]. The company's ability to consistently win competitive federal grants has been a key traction signal, earning it recognition as a "Most Fundable Company" by Pepperdine Graziadio Business School in 2026 [Business Wire, Sep 2026].

The team and a two-product pipeline

Tushar Sharma, the founder and CEO, holds a PhD and has a background that spans process engineering at Intel and medical device development, with the company attributing more than 20 patents to him [Vivifi Medical, retrieved 2026]. Public LinkedIn profiles show a small team that includes design engineers and R&D technicians, suggesting a focus on hands-on prototyping [Nilabha Mukherjea, retrieved 2026]. The company is also recruiting for several remote roles in business development and design, indicating a build-out beyond pure R&D [Vivifi Medical, Sep 2024].

Vivifi is developing two distinct devices. While ReFlow targets BPH, its other program, Calexis-Lap, is a suture-less laparoscopic device intended for the treatment of varicocele, a condition affecting an estimated 30 million men in the U.S. and linked to infertility [BioAccess LA, retrieved 2026]. Robinson Ventures highlighted this device as a minimally invasive solution for immediate and long-lasting reversal when it announced its investment [Robinson Ventures, May 2024]. The company is planning a first-in-human trial for the varicocele treatment in Panama [BioAccess LA, retrieved 2026]. This dual pipeline spreads risk but also divides focus and resources across two separate clinical and regulatory pathways.

Navigating the path to human trials

The most significant hurdle ahead is clinical validation. The ReFlow device remains under FDA investigation and is not yet commercially available [Indexed.vc, retrieved 2026]. The company's published timeline points to a planned first-in-human pilot device study in 2026, following animal studies [LinkedIn, Feb 2026]. Moving from feasibility studies to controlled clinical trials represents a major step-up in cost, operational complexity, and regulatory scrutiny.

• Clinical evidence gap. The promising vascular hypothesis must be proven to safely and effectively improve patient symptoms and urinary flow rates. The initial studies are designed to prove safety, but demonstrating durable efficacy against established MISTs and drugs will be the true test [TrialX, retrieved 2026].
• Commercialization focus. With two devices in development, the company must decide where to concentrate its commercial efforts first. The BPH market is larger and more established, but also far more competitive. The varicocele space has fewer dedicated device competitors but may require educating a broader set of urologists and reproductive specialists.
• Regulatory strategy. While leveraging an approved vascular coupler is a smart regulatory wedge, the novel indication and surgical approach will still require a full de novo or PMA submission to the FDA, a process measured in years and millions of dollars.

The company's answer to these challenges appears to be a disciplined, grant-funded march toward key clinical milestones. Selection into the MedTech Innovator accelerator cohort for 2026 should provide additional mentorship and industry connections [Vivifi Medical, retrieved 2026].

The next twelve months

For Vivifi Medical, the coming year is about transitioning from preclinical promise to clinical reality. The planned first-in-human studies for both ReFlow and Calexis-Lap will generate the first human safety and feasibility data, which will be critical for securing the next round of funding, likely a Series A aimed at financing larger pivotal trials. Success in these early trials would validate the core vascular approach and differentiate the company in two substantial urologic markets.

The patient population here is clear: men with symptomatic BPH who are dissatisfied with medication or wary of traditional tissue-removing surgeries. For them, the current standard of care often feels like a compromise between managing side effects and accepting surgical risk. Vivifi's bet is that a brief, minimally invasive procedure targeting the prostate's blood supply could offer a durable solution without those trade-offs. It is a humane engineering challenge, one that has already convinced some of the most rigorous grant reviewers in the world. The next step is to convince patients and physicians in a clinical setting.

Sources

1. [Vivifi Medical, retrieved 2026] Revolutionary BPH Treatment | https://www.vivifimedical.com/
2. [Perplexity Sonar Pro Brief, retrieved 2026] Vivifi Medical Funding Summary
3. [ClinicalTrial.be, retrieved 2026] Vivifi BPH Treatment Description
4. [TrialX, retrieved 2026] Vivifi Clinical Study Aims
5. [Robinson Ventures, May 2024] Robinson Ventures Invests in Vivifi Medical | https://www.robinsonventures.com/news/article/current/2024/05/17/100043/robinson-ventures-invests-in-vivifi-medical
6. [Tracxn, retrieved 2026] Vivifi Medical Company Profile | https://tracxn.com/d/companies/vivifi-medical/__FvoWC_LFryZ6EMOmxLikCIwv7wFhiOXf052F7lZk7Qo
7. [Business Wire, Sep 2026] Pepperdine Announces 2026 Most Fundable Companies | https://www.businesswire.com/news/home/20260924133294/en/Pepperdine-Graziadio-Business-School-Announces-2026-Most-Fundable-Companies
8. [BioAccess LA, retrieved 2026] Vivifi Medical Varicocele Treatment and Market | https://bioaccessla.com/
9. [Indexed.vc, retrieved 2026] Vivifi Medical Company Profile
10. [LinkedIn, Feb 2026] Vivifi Medical Develops Non-Surgical BPH Treatment | https://www.linkedin.com/posts/lsi-usa_vivifi-medical-is-developing-a-first-in-class-activity-7425236816607264768-55T1
11. [Nilabha Mukherjea, retrieved 2026] LinkedIn Profile
12. [Vivifi Medical, Sep 2024] Careers Page | https://www.vivifimedical.com/careers-modern/